Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N.Y. Suit Against Express Scripts Alleges Overcharges For Generic Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

The suit focuses on Express Scripts' administration of the New York state employee health plan pharmacy benefit. New York AG alleges that PBM overcharged for generic drugs, "disguised" manufacturer rebates and illegally sold plan data to manufacturers and data collection services.

You may also be interested in...



FTC Should Expand Study Of PBM Business Practices, Senators Say

The commission should initiate a second round of data collection focusing on contracts between PBMs and manufacturers, a letter signed by seven senators states. FTC also is urged to collect data on PBM pricing practices for generics.

FTC Should Expand Study Of PBM Business Practices, Senators Say

The commission should initiate a second round of data collection focusing on contracts between PBMs and manufacturers, a letter signed by seven senators states. FTC also is urged to collect data on PBM pricing practices for generics.

New York Attorney General Spitzer Launches Rx Price Comparison Website

The consumer pricing guide is based on a statewide survey but does not signal increased legal scrutiny of pharmacies, Spitzer's office says. The site lists prices for the top 25 prescribed products and allows searches by drug name and location.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel